Global Health Updates: ByteDance AI Spin-off, Cancer Drug Expansion, and Vaccine Challenges

A roundup of current health news highlights ByteDance's AI drug unit achieving a $1.5 billion valuation, the approval of AstraZeneca's cancer drug for NHS use in England, and challenges in US vaccine trust. Meanwhile, Fiji confronts an HIV crisis, and WHO notes progress in the Congo Ebola response.

ByteDance has successfully raised $290 million for its independent AI drug unit, Anew Labs, now valued at $1.5 billion, according to insiders. The Shanghai-based company is pioneering drug discovery through artificial intelligence following its separation from ByteDance, the internet giant known for its social media prowess.

In England, AstraZeneca and Daiichi Sankyo's breast cancer medication Enhertu has been approved for usage within the NHS, extending its accessibility, which began in Scotland in 2023. The pharmaceutical companies aim to secure approvals across other UK regions, including Wales and Northern Ireland.

Amid a resurgence of measles in the United States, confidence in childhood vaccines has declined, as indicated by a recent Reuters/Ipsos poll. Meanwhile, the WHO reports significant progress in combating an Ebola outbreak in the Democratic Republic of Congo, though the risk remains substantial.